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Myosin Binding Protein-C (MyBP-C) comprises a family of accessory proteins that
includes the cardiac, slow skeletal, and fast skeletal isoforms. The three isoforms share
structural and sequence homology, and localize at the C-zone of the sarcomeric A-band
where they interact with thick and thin filaments to regulate the cycling of actomyosin
crossbridges. The cardiac isoform, encoded by MYBPC3, has been extensively studied
over the last several decades due to its high mutational rate in congenital hypertrophic
and dilated cardiomyopathy. It is only recently, however, that theMYBPC1 gene encoding
the slow skeletal isoform (sMyBP-C) has gained attention. Accordingly, during the last 5
years it has been shown that MYBPC1 undergoes extensive exon shuffling resulting in
the generation of multiple slow variants, which are co-expressed in different combinations
and amounts in both slow and fast skeletal muscles. The sMyBP-C variants are subjected
to PKA- and PKC-mediated phosphorylation in constitutive and alternatively spliced sites.
More importantly, missense, and nonsense mutations in MYBPC1 have been directly
linked with the development of severe and lethal forms of distal arthrogryposis myopathy
and muscle tremors. Currently, there is no mammalian animal model of sMyBP-C, but
new technologies including CRISPR/Cas9 and xenografting of human biopsies into
immunodeficient mice could provide unique ways to study the regulation and roles of
sMyBP-C in health and disease.
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INTRODUCTION
Myosin Binding Protein-C (MyBP-C) comprises a family of accessory proteins expressed in striated
muscles, and constitutes 2–4% of the myofibrillar protein mass (Okagaki et al., 1993; Moss et al.,
2015) There are three MyBP-C isoforms encoded by different genes; slow (s) skeletal MyBP-C is
encoded by MYBPC1 present in human chromosome 12, fast (f) skeletal MyBP-C is encoded by
MYBPC2 present in human chromosome 19, and cardiac (c) MyBP-C is encoded by MYBPC3
present in human chromosome 11 (Weber et al., 1993). While cMyBP-C is selectively expressed
in cardiac muscle, fMyBP-C and sMyBP-C co-exist in fast and slow twitch muscles at varying
amounts (Ackermann and Kontrogianni-Konstantopoulos, 2011b). The three isoforms share
structural and sequence homology, primarily consisting of immunoglobulin (Ig), and fibronectin-
III (Fn-III) domains, referred from the NH2-terminus to the COOH-terminus as C1-C10; notably,
the cardiac isoform contains an additional Ig domain, termed C0 (Figure 1; Ackermann and
Kontrogianni-Konstantopoulos, 2010).
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MyBP-C interacts directly with both thick and thin filaments
via its NH2- and COOH-termini. The NH2-terminal domains
C1-M-C2 bind to myosin subfragment 2 (S2) (Gruen et al.,
1999), while the COOH-terminal C10 domain binds to light
meromyosin (LMM) (Okagaki et al., 1993; Harris et al., 2011).
The latter interaction is enhanced by binding of domains C8-C10
to titin that is likely instrumental in the periodic arrangement
of MyBP-C in the C-zone (Craig and Offer, 1976; Freiburg and
Gautel, 1996; Luther et al., 2008; Luther and Craig, 2011). In
addition to binding to S2, the NH2-terminal C0-C1-M-C2 region
contains (relatively weak) binding sites for actin (Kulikovskaya
et al., 2003; Whitten et al., 2008; Ackermann et al., 2009; Shaffer
et al., 2009; Orlova et al., 2011; Bhuiyan et al., 2012), although
recently domains C6-C10 were suggested tomediate high-affinity
binding to actin (Rybakova et al., 2011). The interactions at the
NH2-terminus of MyBP-C are highly dynamic and regulated
via phosphorylation (Figure 1; Gruen et al., 1999; Sadayappan
et al., 2005; Shaffer et al., 2009; Barefield and Sadayappan, 2010).
Accordingly, phosphorylation of cMyBP-C within the M-motif
accelerates contraction by disrupting binding to myosin, thereby
increasing the probability of binding to actin and thus the
rate of force development (Sadayappan and de Tombe, 2012;
Walcott et al., 2015; Colson et al., 2016; Moss, 2016; Previs et al.,
2016).
Although several questions remain unanswered regarding
the (patho)physiology of MyBP-C, early and recent work
(primarily on the cardiac isoform) has postulated that through
its direct binding to both actin and myosin filaments, it
contributes to their assembly and stabilization, modulates
the cycling of actomyosin crossbridges, and regulates the
ATPase activity of myosin (Martyn, 2004; McClellan et al.,
2004; de Tombe, 2006; Oakley et al., 2007; Ackermann
FIGURE 1 | Schematic representation of the three MyBP-C isoforms. Dark and light gray lines correspond to the Pro/Ala-rich region and the M-motif,
respectively, while white and gray rectangles represent Ig and Fn-III domains, respectively. Vertical colored boxes in the Pro/Ala-rich region, the M-motif, Fn-III domain
C7 and the extreme COOH-terminus of sMyBP-C indicate alternative spliced segments. fMyBP-C and cMyBP-C share a conserved linker region between C4 and C5,
denoted in light green. cMyBP-C contains an additional Ig domain, C0, and an isoform-specific insertion in C5 shown in light blue. Phosphorylation sites in the
Pro/Ala-rich region and the M-motif of sMyBP-C are indicated in black, and myopathic mutations in sMyBP-C and fMyBP-C in the M-motif and Ig domains C2 and C8
are shown in red.
and Kontrogianni-Konstantopoulos, 2010, 2013; James and
Robbins, 2011; Rybakova et al., 2011; Ackermann et al.,
2013). Below, we summarize old and new information on
slow skeletal MyBP-C, highlight its direct involvement in
disease pathogenesis and provide a perspective on its roles and
regulation.
sMyBP-C: A COMPLEX SUB-FAMILY OF
PROTEINS REGULATED BY
PHOSPHORYLATION
MyBP-C proteins are highly modular consisting of tandem
immunoglobulin (Ig) and fibronectin-III (Fn-III) modules
interspersed with unique short amino acid segments (Figure 1;
Winegrad, 1999). Ig domain C1 is flanked by a ∼50 amino
acids long Proline/Alanine-rich motif (Pro/Ala-rich motif) and
a ∼100 amino acids long MyBP-C specific motif, referred to
as M-motif (Craig et al., 2014). Single transcripts have been
identified for the mammalian cardiac and fast isoforms, which
result in proteins of ∼140 and ∼130 kDa, respectively (Yasuda
et al., 1995). sMyBP-C is unique, however, as there are several
mammalian variants that have been characterized ranging in
size from 126 to 131 kDa (Ackermann et al., 2015b). This size
variability results from extensive splicing of small amino acid
segments within the Pro/Ala-rich motif, the M-motif, Fn-III
domain C7, and the extreme COOH-terminus (Ackermann and
Kontrogianni-Konstantopoulos, 2011b). The different sMyBP-C
variants are co-expressed in different amounts and combinations
in both slow- and fast-twitch skeletal muscles were they co-exist
with fMyBP-C (Ackermann and Kontrogianni-Konstantopoulos,
2011b, 2013).
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Phosphorylation of cMyBP-C contributes significantly
to contractile regulation (Sadayappan et al., 2005; Stelzer
et al., 2006; Gresham et al., 2014; Gupta and Robbins, 2014;
Gresham and Stelzer, 2016; Mamidi et al., 2016; Moss, 2016;
Previs et al., 2016). Contrary to early studies suggesting that
sMyBP-C is not subjected to phosphorylation (Gruen et al.,
1999), work from our group demonstrated that similar to its
cardiac counterpart, sMyBP-C also undergoes phosphorylation
(Ackermann and Kontrogianni-Konstantopoulos, 2011a).
Interestingly, while phosphorylation of cMyBP-C is restricted
to the M-motif, phosphorylation of sMyBP-C takes place
primarily in the Pro/Ala-rich motif and to a lesser extent in
the M-motif (Ackermann and Kontrogianni-Konstantopoulos,
2011a). In particular, proteomics studies confirmed by the
use of phospho-specific antibodies demonstrated that in the
Pro/Ala-rich motif Ser-59 and Ser-62 are substrates of PKA,
and Thr-84 is substrate of PKC, while in the M-motif Ser-204 is
substrate of both PKA and PKC (Figure 1). Ser-59 and Ser-204
reside in alternatively spliced exons 5 and 10, respectively,
and are therefore present in select slow variants (Ackermann
and Kontrogianni-Konstantopoulos, 2013). Consistent with a
purported important role of phosphorylation in the regulation
of MyBP-C, the phosphorylation levels of sMyBP-C are
differentially altered in relation to different (patho)physiological
stressors. Accordingly, the phosphorylation levels of sMyBP-C
are significantly reduced in fast-twitch Flexor Digitorum Brevis
(FDB) muscle as a function of aging and dystrophy (Ackermann
et al., 2015b). Similarly, the phosphorylation levels of sMyBP-C
are notably decreased in slow-twitch soleus muscle as a result
of aging and dystrophy, but increased in response to fatigue
(Ackermann et al., 2015a). Although these observations are
interesting, a detailed examination of the effects of individual
or combinatorial phosphorylation events in the modulation of
the structural and regulatory activities of sMyBP-C is currently
lacking. It is therefore expected that future endeavors combining
sophisticated in vitro and in vivo approaches will shed light on
the role of phosphorylation in the modulation of sMyBP-C.
MYBPC1: A RECENT MYOPATHIC GENE
MYBPC3 has garnered much attention over the past several
decades due to its prevalent mutational rate leading to congenital
hypertrophic and dilated cardiomyopathy (Harris et al., 2011;
Santos et al., 2012; Kuster and Sadayappan, 2014; Lynch et al.,
2015). It is only recently, however, that mutations in MYBPC1
have been directly associated with inherited myopathies, and
specifically with severe and lethal forms of distal arthrogryposis
myopathy (Table 1) (Markus et al., 2012; Ha et al., 2013; Li
et al., 2015). Contrary to MYBPC3 mutations that mainly
result in truncated proteins and function via haploinsufficiency
(Marston et al., 2012; Kuster and Sadayappan, 2014; Barefield
et al., 2015; Carrier et al., 2015), the currently known MYBPC1
mutations have been suggested to result in poisonous proteins
and manifest in a dominant negative manner after incorporation
into sarcomeres (Markus et al., 2012; Ha et al., 2013; Li et al.,
2015).
Arthrogryposis, also known as arthrogryposis multiplex
congenita, is clinically defined by congenital joint contractures
or movement restriction in multiple body areas (Bayram
et al., 2016). Generally, arthrogryposis occurs as a secondary
effect of decreased fetal joint mobility, which can result from
abnormalities of the central nervous system, the neuromuscular
system, the skeletal system, or connective and cartilage tissue
disturbances. (Filges and Hall, 2013; Haliloglu and Topaloglu,
2013; Hall, 2014; Bayram et al., 2016). Distal arthrogryposis (DA)
myopathies are a group of autosomal dominant arthrogryposis
disorders that mainly involve the distal parts of the limbs
(Bamshad et al., 2009). Ten different types of DA have been
described to date that share common general features, including a
consistent pattern of hand and foot defects, limited involvement
of proximal joints and variable expressivity (Bamshad et al., 1996;
Krakowiak et al., 1998; Stevenson et al., 2006).
DA type-1 (DA-1) is the most common DA myopathy that
affects approximately 1 in 10,000 individuals, and results in
contractures limited to the distal muscles of the hands and feet.
These include clubfoot, vertical talus, camptodactyly, overriding
fingers and ulnar deviations of the fingers with no additional
anomalies (Hall, 1985; Klemp and Hall, 1995; Gurnett et al.,
2010). DA type-2 (DA-2) is a more severe form of DA, also
characterized by contractures of the hands and feet, that is often
accompanied by mild to severe craniofacial anomalies and/or
scoliosis (Kulkarni et al., 2008; Bamshad et al., 2009). There
are two subtypes of DA-2, including DA-2A (Freeman-Sheldon
syndrome) and DA-2B (Sheldon-Hall syndrome) (Kulkarni et al.,
2008; Bamshad et al., 2009; Li et al., 2015). While individuals
with DA-2B Sheldon-Hall syndrome display mild to moderate
facial contractures, individuals with DA-2A Freeman-Sheldon
syndrome havemoderate to severe facial contractures (Beck et al.,
2013; Li et al., 2015).
In the last 5 years, dominant missense mutations inMYBPC1
have been linked to the development of both DA-1 and DA-2
(Gurnett et al., 2010; Li et al., 2015). Specifically, missense
mutations, W236R and Y856H, located in the M-motif and Ig
domain C8, respectively, have been linked to DA-1 (Figure 1;
Gurnett et al., 2010). Both of these substitutions are present
in constitutively expressed exons and thus are contained in
all slow variants (Gurnett et al., 2010; Ackermann et al.,
2015b). ATPase staining of biopsies obtained from the distal
Abductor Hallucis (AH) foot muscle of DA-1 patients carrying
either mutation revealed severe type-I fiber atrophy, although
localization of the mutant proteins was unaltered (Gurnett et al.,
2010). In vitro binding and actin sliding assays demonstrated
that the presence of the W236R and Y856H mutations markedly
diminished the ability of the NH2 and COOH termini of
sMyBP-C, respectively, to bind actin and myosin, and regulate
the formation of actomyosin crossbridges (Ackermann et al.,
2013). Examination of the expression levels of mutant sMyBP-
C that contained the Y856H or the W236R mutation in human
biopsies of AH or gastrocnemius muscles, respectively, revealed
that the total amounts of the protein were significantly reduced
in AH (∼25%), but not gastrocnemius, muscle compared to
controls (Ackermann et al., 2015b). Although puzzling, since
both DA-1 mutations reside in constitutive exons, this finding
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TABLE 1 | Current disease-causing mutations in MYBPC1 and MYBPC2.
Mutation Gene Domain Inheritance Organism Phenotype Disease References
W236R MYBPC1 M-motif Autosomal dominant Human Bilateral clubfoot, camptodactyly with




Gurnett et al., 2010
Y856H MYBPC1 C8 Autosomal dominant
E359K MYBPC1 C2 Autosomal dominant Human Ulnar deviations of the fingers,
camptodactyly, overriding toes and
planovalgus in lower limbs, facial




Li et al., 2015
P319L MYBPC1 C2 Autosomal dominant
R318STOP MYBPC1 C2 Autosomal recessive Human Multiple joint contractures, micrognathia,





Markus et al., 2012
L295R MYBPC1 M-motif Unknown Bull Muscle tremors, muscle weakness,
inability to stand, ataxia, increased muscle




Wiedemar et al., 2015
T236I MYBPC2 M-motif Compound heterozygote
with GPR126 homozygous
R7STOP mutation
Human Narrow thorax, polyhydramnios during
development, and postnatal death
Unclassified Distal
Arthrogryposis
Bayram et al., 2016
S255T MYBPC2 M-motif
is in agreement with the selective effects of DA-1 on distal
muscles, and the lack of a myopathic phenotype in proximal
muscles. Interestingly, the phosphorylation profile of mutant
sMyBP-C containing the Y856H mutation was also altered in
the affected AH muscle, whereas the phosphorylation profile
of sMyBP-C carrying the W236R mutation was unchanged in
gastrocnemius muscle (Ackermann et al., 2015b). Accordingly,
use of a panel of phospho-specific antibodies and phos-tag gel
electrophoresis revealed that mutant sMyBP-C harboring the
Y856H mutation in AH muscle was phosphorylated at all four
known residues, however the extent of phosphorylation was
decreased by 30–70% for individual phospho-sites, compared to
control tissue (Ackermann et al., 2015b).
Recently, two novel autosomal dominant missense mutations
in Ig domain C2 of sMyBP-C, P319L and E359K, were linked to
the development of DA-2 (Figure 1) (Li et al., 2015). Although
a mechanistic understanding of the effect(s) of these mutations
is still lacking, it is tempting to speculate that they may affect
binding to the S2 portion of myosin and/or actin via induction
of an unfavorable conformation (P319L) or altered electrostatic
interactions (E359K). Future studies using a combination of
biochemical, structural, biophysical and in vivo approaches will
address these hypotheses.
In addition to DA-1 and DA-2, MYBPC1 has been directly
linked to the development of a neonatal lethal form of
arthrogryposis myopathy, referred to as Lethal Congenital
Contracture Syndrome type-4 (LCCS-4; Markus et al., 2012).
Specifically, an autosomal recessive nonsense mutation in
Ig domain C2 of sMyBP-C results in a premature stop
codon at amino acid 318 (R318Stop; Figure 1). Given the
recessive inheritance of LCCS-4, along with the absence of
any phenotypic or functional abnormalities in the heterozygous
carriers, it is highly likely that the R318Stop mutation results
in loss of sMyBP-C rather than a poisonous truncated protein.
Nevertheless, if themutant protein is indeed expressed, it will lack
domains C3-C10 downstream of Ig C2, which contain binding
sites for LMM, titin and obscurin (Okagaki et al., 1993; Freiburg
and Gautel, 1996; Ackermann et al., 2009).
In addition to mutations in the humanMYBPC1 gene that are
associated with severe and lethal forms of DA, a new mutation
in the bullMYBPC1 gene was recently identified, too (Wiedemar
et al., 2015). In particular, a 2-week old female calf presented with
muscle tremors since birth, standing difficulty and reduced spinal
reflexes (Wiedemar et al., 2015). Whole genome sequencing
analysis revealed a de novo missense mutation, L295R, localized
in the M-motif following the Ig domain C1, similar to the human
W236R mutation. Although the phenotypic manifestation of the
L295Rmutation is reminiscent of DA-1, it is further accompanied
by muscle tremors, which is indicative of a more complex and/or
severe myopathy. At this time, a mechanistic understanding of
the effects of the L295R mutation is lacking.
As novel mutations in MYBPC1 are being identified in
the mammalian genome underscoring its role in skeletal
muscle (patho)physiology, it is worth mentioning that recently
MYBPC2, encoding fMyBP-C, was also linked to an unclassified,
neonatal lethal DA in the form of a compound heterozygote
(Bayram et al., 2016). Specifically, a patient presenting with
narrow thorax, polyhydramnios during fetal development, and
neonatal death was found to possess two missense mutations
in MYBPC2, T236I and S255T, located in the M-motif. The
same patient also contained an R7Stop homozygous mutation
in the GPR126 gene, which encodes a G-protein coupled
receptor that regulates neural, cardiac, and ear development
(Patra et al., 2014; Bayram et al., 2016). Although mutations in
GPR126 have been linked with isolated arthrogryposis multiplex
congenital (Ravenscroft et al., 2015), it is likely that the
additional mutations in MYBPC2 contributed to the postnatal
lethality of the carrier due to accumulating anomalies in motor
neurons and muscle structure and function (Bayram et al.,
2016).
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Although at the current time limited, the above studies
clearly indicate that mutations in the genes that encode the
skeletal MyBP-C proteins (and especially the slow isoform) are
intimately associated with the development of severe and lethal
myopathies. Obviously, the challenge now lies in deciphering
the cell processes that are altered or compromised due to
individual mutations using sophisticated and high resolution in
vitro approaches and appropriate in vivomodels.
IN VIVO MODELS OF MYBPC1:
PERSPECTIVES AND ENDEAVORS
Over the last four decades, a tremendous emphasis has been
placed on the regulation and roles of cMyBP-C due to its
direct involvement in congenital heart disease resulting in the
generation of multiple animal models (Harris et al., 2002;
Sadayappan et al., 2005; Carrier et al., 2015). This is not
the case for sMyBP-C (or fMyBP-C). Remarkably though,
the direct association of MYBPC1 with the development of
severe and lethal forms of DA has tunneled the interest of
the scientific community toward the molecular and functional
characterization ofMYBPC1, too.
A recent study used the zebrafish model and antisense
morpholinos to down-regulate the expression of MYBPC1 (Ha
et al., 2013). Knock-down zebrafish exhibited severe ventral
body curvature, decreased mobility, and early lethality, along
with impaired sarcomeric development and reduced number of
myofibrils (Ha et al., 2013). Moreover, overexpression of mutant
sMyBP-C proteins carrying either of the DA-1mutations,W236R
or Y856H, in zebrafish demonstrated that both mutant proteins
exerted a dominant negative effect, resulting in embryos with
mild bent body curvature, impaired mobility, and muscles with
less tightly compacted fibers compared to controls (Ha et al.,
2013).
Apart from the zebrafish model, no mammalian MYBPC1
animal models have been generated yet. Our group has been
systematically working on sMyBP-C for the last 5 to 6 years
focusing on its molecular characterization, regulation and
functional evaluation. Given the unique complexity of MYBPC1
(Ackermann and Kontrogianni-Konstantopoulos, 2010, 2011b,
2013), its early expression during fetal development preceding
that of MYBPC2 (Gautel et al., 1998; Kurasawa et al., 1999),
and the neonatal lethality of LCCS-4 patients, who most likely
lack sMyBP-C, we predict that a constitutive MYBPC1 null
model would be postnatal lethal. If this is the case, such a
model is still worth generating, since it will highlight the
non-redundant roles of sMyBP-C and fMyBP-C, and will
allow the study of the structural and regulatory roles of
sMyBP-C in myofibrillar assembly and contractility during
embryogenesis and (early) postnatal life. Obviously, conditional
null models would circumvent the potential neonatal lethality
of a constitutive MYBPC1 knock-out allowing the detailed
investigation of the roles of sMyBP-C in modulating actomyosin
contractility in mature muscles. Along the same lines, knock-in
models carrying the DA-1, DA-2, or LSSC-4 mutations are also
lacking, limiting our understanding of the effects of the respective
mutations to in vitro studies, which although informative, need to
be accompanied by in vivo data.
Type II bacterial Clustered Regularly Interspaced Short
Palindromic Repeats-associated protein Cas9 (CRISPR-Cas9)
mediated genome editing has emerged as a powerful tool for
genetic manipulation. Unlike small interfering RNAs (siRNAs)
or short hairpin RNAs (shRNAs), the CRISPR-Cas9 system is
able to knockout individual gene expression at the genomic level
with minimal off-target effects (Zhang et al., 2014; Humphrey
and Kasinski, 2015). Conversely, CRISPR/Cas9 technology is also
being refined for generating knock-in models to recapitulate
disease development (Chu et al., 2015; Tu et al., 2015). As
the technology becomes increasingly popular, the generation of
constitutive or conditional MYBPC1 knock-out and knock-in
mouse models should be feasible in a fairly short amount of time.
In vivo gene transfer (IVGT) followed by electroporation is
also an efficient, non-viral method for gene delivery that has been
successfully used by several groups (Gehl, 2003; Spanggaard et al.,
2012; Hu et al., 2014). Although the mechanisms underlying
DNA electrotransfer are not yet fully elucidated, it has been
suggested that permeabilization of the cell membrane as well
as electrophoretic migration of the DNA are involved (Mir
et al., 1999; Bureau et al., 2000; Golzio et al., 2002; Satkauskas
et al., 2002). Muscle tissue is a favorable target for gene
electrotransfer as it is easily accessible, allowing high-level, long-
term transgenic expression (Mir et al., 1999; Lucas and Heller,
2001; Spanggaard et al., 2012). Such an approach could therefore
be employed to knock-down (via shRNA technology) or knock-
out (via CRISPR-Cas9 technology)MYBPC1 in a muscle-specific
manner, circumventing the potential neonatal lethality of a
constitutive null model, and enabling the functional examination
of different slow variants given that they are expressed in
distinct combinations among skeletal muscles. Moreover, IVGT
combined with electroporation could be used to overexpress
myopathic forms of sMyBP-C. Although the stoichiometry of
endogenous to exogenous proteins is an important issue to
consider, it could potentially be alleviated by inducible, titratable
expression systems. Notably, IVGT experiments are particularly
beneficial as the effects of gene knock-down, knock-out or knock-
in experiments can be analyzed from the single fiber to the whole
animal level. For instance, many groups have taken advantage
of permeabilized muscle fiber preparations of human biopsies or
pre-clinical mouse models to elucidate the (patho)physiology of
cMyBP-C (Harris et al., 2002; Stelzer et al., 2006; James and
Robbins, 2011; Wang et al., 2016).
An alternative to generating animal models of muscle disease
has emerged in the last few years, entailing the development
and propagation of grafts of myopathic or dystrophic human
muscle tissue in mice (Riederer et al., 2012; Meng et al.,
2014; Sakellariou et al., 2015). This approach has tremendous
benefits, given that animal models often fail to replicate the
features of human muscle disease. Along these lines, a recent
study reported the generation of xenografts from human bicep
muscle biopsies of facioscapulohumeral muscular dystrophy
(FSHD) patients that were transplanted into the hindlimbs of
immunodeficient NOD-Rag1nullIL2rynull mice (Sakellariou et al.,
2015). The engrafted human muscle was efficiently regenerated
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and innervated, and displayed normal contractile properties
(Sakellariou et al., 2015). While the xenografting model approach
is still being perfected, the largest hurdle is the unavailability
of fresh muscle biopsies and the lack of organized biobanks;
obviously, this is a major issue that applies to MYBPC1 related
myopathies, as well. Nevertheless, the xenografting model could
prove to be an extremely useful tool for studying the effects of
human myopathies in vivo, since it may recapitulate the course
of disease development more faithfully compared to engineered
models of C. elegans, zebrafish, or mouse that are commonly used
to date.
CONCLUSIONS
Slow skeletal MyBP-C has recently attracted considerable interest
primarily due to its direct involvement in the development
of severe and lethal forms of distal arthrogryposis myopathy.
Contrary to the fast and cardiac isoforms, sMyBP-C comprises
a subfamily of proteins with possibly distinct structural
and regulatory roles, which are modulated by constitutive
and variant-specific phosphorylation events. Given the recent
involvement of MYBPC1 in severe and lethal myopathies, we
predict that a comprehensive, multidisciplinary evaluation of its
regulation and roles in health and disease is in order.
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